Opaleye Management as of Dec. 31, 2024
Portfolio Holdings for Opaleye Management
Opaleye Management holds 39 positions in its portfolio as reported in the December 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Harrow Health (HROW) | 23.4 | $134M | 4.0M | 33.55 | |
| Tg Therapeutics (TGTX) | 11.9 | $68M | 2.3M | 30.10 | |
| Codexis (CDXS) | 7.4 | $42M | 8.8M | 4.77 | |
| Eton Pharmaceuticals (ETON) | 6.6 | $38M | 2.9M | 13.32 | |
| Ocular Therapeutix (OCUL) | 6.5 | $37M | 4.3M | 8.54 | |
| Arvinas Ord (ARVN) | 5.9 | $34M | 1.6M | 20.70 | |
| Rhythm Pharmaceuticals (RYTM) | 4.9 | $28M | 500k | 55.98 | |
| Immunome (IMNM) | 3.8 | $22M | 2.0M | 10.62 | |
| Liquidia Corporation Com New (LQDA) | 3.5 | $20M | 1.7M | 11.76 | |
| Edgewise Therapeutics (EWTX) | 2.2 | $13M | 480k | 26.70 | |
| Ginkgo Bioworks Holdings Class A New (DNA) | 2.1 | $12M | 1.2M | 9.82 | |
| Cargo Therapeutics (CRGX) | 1.9 | $11M | 750k | 14.42 | |
| Protara Therapeutics Com Stk (TARA) | 1.7 | $9.6M | 1.8M | 5.28 | |
| Trevi Therapeutics (TRVI) | 1.7 | $9.5M | 2.3M | 4.12 | |
| Jasper Therapeutics Com New (JSPR) | 1.5 | $8.6M | 400k | 21.38 | |
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 1.5 | $8.4M | 325k | 25.70 | |
| Acelyrin | 1.3 | $7.2M | 2.2M | 3.21 | |
| Nurix Therapeutics (NRIX) | 1.2 | $7.1M | 379k | 18.84 | |
| Xoma Corp Del Com New (XOMA) | 1.1 | $6.6M | 250k | 26.28 | |
| Vaxcyte (PCVX) | 1.1 | $6.1M | 75k | 81.86 | |
| Gossamer Bio Note 5.000% 6/0 (Principal) | 1.1 | $6.1M | 12M | 0.53 | |
| Zentalis Pharmaceuticals (ZNTL) | 0.9 | $5.4M | 1.8M | 3.03 | |
| Biodesix (BDSX) | 0.9 | $5.3M | 3.5M | 1.53 | |
| Karyopharm Therapeutics Note 3.000%10/1 (Principal) | 0.8 | $4.7M | 6.0M | 0.78 | |
| Nuvalent Inc-a (NUVL) | 0.8 | $4.6M | 59k | 78.28 | |
| Gossamer Bio (GOSS) | 0.7 | $4.1M | 4.5M | 0.90 | |
| Protagonist Therapeutics (PTGX) | 0.7 | $4.1M | 105k | 38.60 | |
| Essa Pharma Com New (EPIX) | 0.7 | $4.0M | 2.2M | 1.79 | |
| Abcellera Biologics (ABCL) | 0.5 | $2.8M | 965k | 2.93 | |
| Urogen Pharma (URGN) | 0.4 | $2.3M | 220k | 10.65 | |
| Rezolute Com New (RZLT) | 0.4 | $2.3M | 465k | 4.90 | |
| Immatics Nv Ordinary Shares (IMTX) | 0.2 | $1.2M | 165k | 7.11 | |
| Ibio Com New (IBIO) | 0.2 | $919k | 375k | 2.45 | |
| Lexeo Therapeutics (LXEO) | 0.1 | $855k | 130k | 6.58 | |
| Regenxbio Inc equity us cm (RGNX) | 0.1 | $618k | 80k | 7.73 | |
| Ventyx Biosciences (VTYX) | 0.1 | $613k | 280k | 2.19 | |
| Pepgen (PEPG) | 0.1 | $417k | 110k | 3.79 | |
| Stoke Therapeutics (STOK) | 0.0 | $276k | 25k | 11.03 | |
| Adagio Med Hldgs (ADGM) | 0.0 | $116k | 111k | 1.05 |
